



- Healthcentric Advisors
- Qlarant

QIN-QIO

Quality Innovation Network -
Quality Improvement Organizations
CENTERS FOR MEDICARE & MEDICAID SERVICES
iQUALITY IMPROVEMENT & INNOVATION GROUP

Vaccination History Form

Facility Name: _____

Resident Name: _____ Today's Date: _____

DOB: _____ Allergies: _____

History of reaction to vaccine, please describe: _____

Routine Vaccination History Documentation

13-valent pneumococcal conjugate vaccine (PCV13, Prevnar 13®):

Date given after age 18: _____

- No evidence resident received prior to admission
 - Vaccine screening recommended:
 - MD reviewed and ordered
 - Placed on MAR for administration
 - Resident/health care proxy (HCP) declined vaccination
 - Medically contraindicated
- Vaccine not required: _____

23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax®23):

Date given prior to age 65: _____

After age 65 and at least after 5 years from 1st dose date: _____

and one year from PCV13 date: _____

- No evidence resident received prior to admission
 - Vaccine screening recommended:
 - MD reviewed and ordered
 - Placed on MAR for administration
 - Resident/HCP declined vaccination
 - Medically contraindicated

Resident Name: _____

COVID-19 Vaccination: Brand: _____

Dose #1 Date: _____ Dose #2: Date _____ Booster Date: _____

- Vaccine series completed, vaccine not required
- No evidence resident received prior to admission
 - Vaccine screening recommended:
 - MD reviewed and ordered
 - Placed on MAR for administration
 - Resident/HCP declined vaccination
 - Medically contraindicated

Influenza: Circle the type below.

High Dose/Standard Date: _____ High Dose/Standard Date: _____

High Dose/Standard Date: _____ High Dose/Standard Date: _____

High Dose/Standard Date: _____ High Dose/Standard Date: _____

- No evidence resident received prior to admission for current influenza season
- Vaccine screening recommended:
 - MD reviewed and ordered
 - Placed on MAR for administration
 - Resident/HCP declined vaccination
 - Medically contraindicated

References:

[COVID-19 Vaccine FAQs for Healthcare Professionals | CDC](#) accessed 3/18/2021

[PneumoRecs VaxAdvisor: Vaccine Provider App | CDC](#) accessed 3/18/2021

Matanock, A., Lee, G., Gierke, R., Kobayashi, M., Leidner, A., & Pilishvili, T. (2019). Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices (APIC).

This material was prepared by the IPRO QIN-QIO, a Quality Innovation Network-Quality Improvement Organization, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication 12SOW-IPRO-QIN-T3-AA-21-461